Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
USING GENETIC ENGINEERING TO IMPROVE THE BISPECIFIC ANTIBODY PLATFORM FOR MDS THERAPY
KTH.
Show others and affiliations
2017 (English)In: Leukemia research: a Forum for Studies on Leukemia and Normal Hemopoiesis, ISSN 0145-2126, E-ISSN 1873-5835, Vol. 55, S126-S126 p.Article in journal (Refereed) Published
Place, publisher, year, edition, pages
Pergamon Press, 2017. Vol. 55, S126-S126 p.
National Category
Cancer and Oncology
Identifiers
URN: urn:nbn:se:kth:diva-220647ISI: 000417653300217OAI: oai:DiVA.org:kth-220647DiVA: diva2:1173119
Conference
14th International Symposium on Myelodysplastic Syndromes (MDS), MAY 03-06, 2017, Valencia, SPAIN
Note

QC 20180111

Available from: 2018-01-11 Created: 2018-01-11 Last updated: 2018-01-11Bibliographically approved

Open Access in DiVA

No full text

Search in DiVA

By author/editor
Brandt, L.Guldevall, K.
By organisation
KTH
In the same journal
Leukemia research: a Forum for Studies on Leukemia and Normal Hemopoiesis
Cancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar

urn-nbn

Altmetric score

urn-nbn
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf